ETF PROAI
PSILAdvisorSharesACTIVE

AdvisorShares Psychedelics ETF

$21.85-0.95% vs prior close
15.632752-WK

Price through Oct 2 · Flows through unavailable. Figures use the latest available records, not a live quote. Fund details retrieved Oct 2. Holdings snapshot retrieved Oct 2.

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.

Price & daily flows
24.421.218.0421.85DAILY NET FLOWOct 2Feb 2Jun 2Oct 2

SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 3Y SHOWN

The desk’s read

Recent fund-flow records are unavailable, while the price has returned +27.3% so far this year. At 0.99% a year it is not the cheapest way in — JDOC has a reported fee of 0.65%.

COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH

$5133.00Tassets under management
0.99%expense ratio · $99 per $10,000 a year
—net flow, trailing month
35Kavg daily volume, 30 days
26holdings
2021listed September 16, 2021 · beta 1.23
Sector weights
Healthcare100%
Health Technology95.32%
Health Services3.77%
Other1.61%
Mutual fund0.91%
PORTFOLIO COMPOSITION, LATEST DISCLOSURE
Country weights
United States54.05%
Canada22.65%
Other9.58%
United Kingdom8.45%
Germany5.22%
Australia4.92%
Ireland4.7%
PORTFOLIO COMPOSITION, LATEST DISCLOSURE
Performance
1 week-5.8%
1 month-12.0%
3 months-5.9%
6 months+29.3%
YTD+27.3%
1 year+11.2%
3 years—

PRICE RETURN, DISTRIBUTIONS NOT REINVESTED

Net flows
1 week—
1 month—
3 months—
YTD—
1 year—

CREATION/REDEMPTION DOLLARS, DAILY RECORDS

The risk read
27%realized volatility, 30 days (annualized)
40%realized volatility, 1 year
-27.6%deepest fall from a peak, 1 year
-18.5%latest close versus that peak

VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK

Options tape
42calls · latest snapshot
—puts · latest snapshot
—put/call ratio
20Kshares traded
The case against PSIL

Due diligence cuts both ways. These funds sit on the same shelf and beat PSIL on at least one dimension that matters — the fee, the asset base, or where the money is going.

FundFeeAssetsFlow, 1MThe case
SPDW State Street SPDR Portfolio Developed World ex-US ETF0.03%$41.5B+$286M-96bp on fee · +$286M in over the monthHead-to-head
SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF0.03%$18.2B+$199M-96bp on fee · +$199M in over the monthHead-to-head
IDEV iShares Core MSCI International Developed Markets ETF0.04%$32.9B+$497M-95bp on fee · +$497M in over the monthHead-to-head
IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF0.04%$23.7B+$575M-95bp on fee · +$575M in over the monthHead-to-head
IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF0.04%$18.6B+$412M-95bp on fee · +$412M in over the monthHead-to-head
Sign in to save this to The RecordA timestamped copy for the file — documentation, not advice.
InstrumentsHarvest substitutesTrade cost at $1MClient tearsheetStress this fund
THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.